Live tape
Top 8, mentions 7d17,656MSFT3,331 mentions▲ +0.08GOOGL2,705 mentions▲ +0.05AAPL2,320 mentions▲ +0.07META2,240 mentions▲ +0.04SPCX1,997 mentions▲ +0.06SNDK1,870 mentions▲ +0.06NVDA1,761 mentions▲ +0.07QQQ1,432 mentions▲ +0.04

Equity · Healthcare

TGTX

TG Therapeutics, Inc. · NasdaqCM

$55.00 +0.16% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart Chart by TradingView

The chart above plots the price of TGTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 55 sessions over that window: $34.00 on 1 May 2026 through $55.00 on 17 July 2026. Finazon · prior-day close.

Market cap $8.4B
P/E (TTM) 20.0
52-week range $26.40 – $59.00
Avg volume 421.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

TGTX insider trades

SEC Form 4

TGTX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 24 November 2025.

Date Insider Type Shares Value
24 Nov 2025 Echelard Yann Sell 5,000 $163K
11 Sep 2025 Lonial Sagar Sell 20,852 $672K
Compensation mechanics (1 filing)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
05 Nov 2025 WEISS MICHAEL S CEO Gift 4,668,843

TGTX reported financials

SEC EDGAR XBRL

TGTX reported revenue of $616.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $447.2M.

Figure Reported Period
Revenue $616.3M 31 Dec 2025 fiscal year
Net income $447.2M 31 Dec 2025 fiscal year
Diluted EPS $2.77 31 Dec 2025 fiscal year
Total assets $1.5B 31 Mar 2026 at period end
Total equity $583.1M 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

TGTX earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $0.12
31 Dec 2025 FY 2025 $2.77
30 Sep 2025 Q3 2025 $2.43
30 Jun 2025 Q2 2025 $0.17

Reported figures & scheduled dates · SEC EDGAR filings

TGTX institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a TGTX position for the quarter ended 31 Mar 2026 — a combined $184.5M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Citadel Advisors Added +90.2% shares 1,922,889 $63.9M
Two Sigma Investments Added +45.4% shares 1,542,312 $51.2M
D. E. Shaw & Co. Held (±25%) −15.7% shares 590,047 $19.6M
Man Group Trimmed −62.9% shares 354,697 $11.8M
AQR Capital Management Added +153.1% shares 344,189 $11.4M
Renaissance Technologies New position 340,900 $11.3M
Bridgewater Associates Trimmed −33.7% shares 311,415 $10.3M
Millennium Management Trimmed −81.9% shares 122,587 $4.1M
Marshall Wace New position 25,693 $854K

Source: SEC EDGAR 13F filings

TGTX fails-to-deliver

SEC CNS data

On 30 Jun 2026, 496 shares of TGTX failed to deliver (about $28K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 496 $28K <0.001%
29 Jun 2026 1 $56 <0.001%
18 Jun 2026 6,209 $320K 0.004%
15 Jun 2026 25,844 $1.3M 0.017%

Source: SEC fails-to-deliver (CNS) data